



7-9-04

IFW

PTO/SB/21 (04-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/718,328
	Filing Date	November 20, 2003
	First Named Inventor	Nizal Samuel Chandrakumar
	Art Unit	1614
	Examiner Name	Unknown
Total Number of Pages in This Submission	Attorney Docket Number	3077/0A/US(6794-000092/US/DVA)

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC)  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  <b>HDP Form-1449; References; Return Receipt Postcard</b>
<div>Remarks</div>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	James E. Davis, PTO Reg. No. 47,516 Harness, Dickey & Pierce, P.L.C.
Signature	
Date	July 8, 2004

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	James E. Davis	Express Mail Label No.	EV 298497168 US
Signature		Date	July 8, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**EV 298497168 US**



Attorney Docket No: 3077/0A/US  
HDP Docket No: 6794-000092/US/DVA

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Chandrakumar et al.  
Serial No: 10/718,328  
Filed: November 20, 2003  
For: Heterocyclic Glycyl  $\beta$ -Alanine Derivatives  
Art Unit: 1614  
Examiner: Unknown  
Attorney Docket No: 3077/0A/US  
HDP Docket No: 6794-000092/US/DVA

July 8, 2004

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Madam/Sir:

In accordance with 37 CFR §1.97 and §1.98, and MPEP §609, and in compliance with the duty of disclosure set forth in 37 CFR §1.56 Applicants hereby submit the references cited on the attached Form PTO-1449 for consideration and entry in the above-referenced patent application.


Applicants submit this Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents Applicants are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104(a) and §1.106(b) and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.

References 1-16 cited in this Information Disclosure Statement were previously cited or submitted to the office and considered in parent application Serial No. 09/289,140. Therefore, copies of the references are not being provided in accordance with 37 CFR §1.98(d) and MPEP §609 Part III(2). However, Applicants will readily provide copies of such references if necessary. Further, an English translation of the abstract for reference 7, EP 0 820 991 A2 was

not provided in the parent application but is being submitted with this Information Disclosure Statement.


Applicants believe that this Information Disclosure Statement is being submitted before the mailing of a first Office action on the merits and thus no fee is owed. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

Respectfully submitted,


  
James E. Davis, PTO Reg. No. 47,516  
Harness, Dickey & Pierce  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
(314) 726-7500 (tel)  
(314) 726-7501 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on July 8, 2004 with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

  
Peggy Marie Leslie

JED/ECR



FORM PDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 2

ATTORNEY DOCKET No.	SERIAL No.
3077/0A/US	10/718,328
APPLICANT	
Chandrakumar et. al	
FILING DATE	GROUP
November 20, 2003	Unknown

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.		5,120,859	06/09/1992	Webb	548/557	09/22/1989
2.		5,688,913	11/18/1997	Arrhenius	530/330	05/05/1995

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
3.		WO 97 08145	03/06/1997	PCT	C07D 213/55		
4.		CA 2,211,270	07/23/1997	Canada	C07D 233/44		
5.		WO 98 08840	03/05/1998	PCT	C07D 401/06		
6.		WO 91 04247	04/04/1991	PCT	C07D 207/16		
7.		EP 0 820 991 A2	01/28/1998	Europe	C07D 239/16	X abstract	

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**


Ref. Desig.	Examiner's Initials	
8.		Carron, <i>Cancer Res</i> 58, 1930-35, 1988
9.		Dutta, <i>Journal of Peptide Science</i> 6(7): 321-341, July 2000
10.		Komoriya, A., <i>J. Biol. Chem.</i> 266(23):15075-15079, August 1991
11.		Haworth, D., <i>Br. J. Pharmacol.</i> 126(8), 1751-1760, April 1999
12.		Yang Y., <i>European Journal of Immunology</i> 28(3), 995-1004, March 1998
13.		Haubner, <i>J. Am. Chem. Soc.</i> 118, 7881, 1996

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EVP 298497168 US



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE**  
**INFORMATION DISCLOSURE CITATION**  
 (Use several sheets if necessary)

Sheet 2 of 2

ATTORNEY DOCKET No.	SERIAL No.
3077/0A/US	10/718,328
APPLICANT	
Chandrakumar et. al	
FILING DATE	GROUP
November 20, 2003	Unknown

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ref. Desig.	Examiner's Initials	
14.		Nicosia, <i>American Journal of Pathology</i> 138(4) 829-33, April 1991
15.		Belo, <i>Inflammation</i> 25(2) 91-6, 2001
16.		Mundhenke, <i>Clinical Cancer Research</i> 7(11) 3366-74, 2001
17.		Seftor et al., Role of the $\alpha_v\beta_3$ integrin in human melanoma cell invasion, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 1557-1561, March 1992
18.		Montgomery et al., Integrin $\alpha_v\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, <i>Proc. Natl Acad. Sci. USA</i> , Vol. 91, pp. 8856-8860, September 1994
19.		Brooks et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, <i>Cell</i> , Vol. 79, pp. 1157-1164, December 1994
20.		Adamis et al., Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy, <i>American Journal of Ophthalmology</i> , Vol. 118, pp. 445-450, October 1994
21.		Peacock et al., Angiogenesis Inhibition Suppresses Collagen Arthritis, <i>J. Exp. Med.</i> , Vol. 175, pp. 1135-1138, April 1992
22.		Brooks et al., Requirement of Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis, <i>Science</i> , Vol. 264, pp. 569-571, April 1994
23.		Sato et al., Echistatin Is a Potent Inhibitor of Bone Resorption in Culture, <i>J. Cell Biology</i> , Vol. 111, pp. 1713-1723, October 1990
24.		Fisher et al., Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, an "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, <i>Endocrinology</i> , Vol. 132, No. 3, pp. 1411-1413, 1993
25.		Choi et al., Inhibition of neointimal hyperplasia by blocking $\alpha_v\beta_3$ integrin with a small peptide antagonist GpenGRGDSPCA, <i>J. Vasc. Surg.</i> , Vol. 19(1), pp. 125-134, 1994
26.		White, J.M., Integrins as virus receptors, <i>Current Biology</i> , Vol. 3(9), pp. 596-599, 1993

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.